Study of deuremidevir for RSV in infants and young children
Part of Infections clinical trials.
This trial is testing a new medicine called deuremidevir for babies and young children with RSV infection. It is for those who have symptoms like fast breathing and wheezing, and have been sick for no more than 96 hours.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 1 month and 36 months old (under 3 years).
- Your child weighs at least 2.5 kg and no more than 20 kg.
- Your child has tested positive for RSV and has been sick for 96 hours or less.
- Your child has fast breathing and wheezing, and a certain severity score from their doctor.
- If your child is under 12 months, their head size must be normal for their age.
- Your child does not have certain other infections, severe heart or lung problems, or other conditions that might make the medicine unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
Hear when a new Respiratory Syncytial Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.